Vanguard Capital Wealth Advisors purchased a new position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 5,300 shares of the biotechnology company’s stock, valued at approximately $295,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Carillon Tower Advisers Inc. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $38,720,000. Alyeska Investment Group L.P. purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $26,011,000. TimesSquare Capital Management LLC purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $21,521,000. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Sarepta Therapeutics by 63.4% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock valued at $48,564,000 after buying an additional 338,737 shares in the last quarter. Finally, Element Capital Management LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $17,706,000. Institutional investors own 84.93% of the company’s stock.
Shares of Sarepta Therapeutics Inc (NASDAQ SRPT) opened at $78.78 on Tuesday. The stock has a market cap of $5,258.05, a PE ratio of -98.48 and a beta of 1.52. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. Sarepta Therapeutics Inc has a 52-week low of $28.14 and a 52-week high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The business had revenue of $57.30 million during the quarter, compared to analysts’ expectations of $57.33 million. During the same period in the previous year, the company posted ($0.71) EPS. Sarepta Therapeutics’s revenue for the quarter was up 961.1% on a year-over-year basis. equities research analysts anticipate that Sarepta Therapeutics Inc will post -1.18 earnings per share for the current year.
SRPT has been the topic of a number of analyst reports. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $75.00 target price on the stock. HC Wainwright set a $75.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Oppenheimer reiterated a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Finally, Nomura boosted their price target on shares of Sarepta Therapeutics to $96.00 and gave the stock a “buy” rating in a research note on Friday, March 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $75.31.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.